Kamijo K, Nagata A, Sato Y
Kamijo Thyroid Research Institute, Sapporo, Japan.
Endocr J. 1999 Jun;46(3):397-403. doi: 10.1507/endocrj.46.397.
The Inui and Ochi group recently reported that cAMP production by porcine thyroid cells (PTC) was augmented more by polyethylene glycol (PEG) 22.5% precipitated fractions from almost all Graves' sera than those of PEG 12.5%. In the present study, thyroid stimulating immunoglobulin (TSI) activity was determined with PTC and prepared crude Ig fractions precipitated by two different concentrations of PEG (final concentrations 13.5% and 22.5%) from sera obtained from 117 Graves' patients. The activity of TSI determined by the PEG 13.5% assay and activity determined by the PEG 22.5% assay were designated as thyroid-stimulating antibody (TSAb) and sTSAb, respectively. At first we studied 55 TSAb-positive patients with untreated hyperthyroid Graves' disease and classified them according to the TSAb activity-below 500% (group 1) and above 500% (group 2). The positive stimulatory effect, arbitrarily defined as the ratio of sTSAb to TSAb, being more than 1.2, was observed in 85% of patients, and group 1 had a significantly (P<0.025) greater stimulatory effect (34/35, 97.1%) than group 2 (13/20, 65%). Subsequently, in 29 TSAb-negative patients, sTSAb was measured and detected in 26 (89.7%). Finally, sTSAb, TSAb and TBII were compared between patients presenting with recurrent Graves' disease and those with silent thyroiditis after withdrawal of antithyroid drug treatment for Graves' disease. sTSAb was detected in all 14 relapsed patients, but none of the 9 patients with silent thyroiditis had detectable sTSAb. In contrast, TSAb and TBII activities were found in only 7 (50.0%) of the 14 relapsed cases. The present paper demonstrated that the assay with a higher PEG concentration was found to be sensitive, specific and useful for the diagnosis and follow-up of Graves' disease after drug withdrawal, although the underlying mechanism remains unclear.
井口和奥池研究小组最近报告称,与12.5%的聚乙二醇(PEG)相比,几乎所有格雷夫斯病患者血清中22.5%的PEG沉淀组分对猪甲状腺细胞(PTC)产生环磷酸腺苷(cAMP)的促进作用更强。在本研究中,用PTC测定甲状腺刺激免疫球蛋白(TSI)活性,并从117例格雷夫斯病患者的血清中制备两种不同浓度PEG(终浓度13.5%和22.5%)沉淀的粗免疫球蛋白组分。通过PEG 13.5%检测法测定的TSI活性和通过PEG 22.5%检测法测定的活性分别称为甲状腺刺激抗体(TSAb)和sTSAb。首先,我们研究了55例未经治疗的甲状腺功能亢进型格雷夫斯病且TSAb阳性的患者,并根据TSAb活性将他们分为低于500%(第1组)和高于500%(第2组)。在85%的患者中观察到阳性刺激效应,将其任意定义为sTSAb与TSAb的比值大于1.2,第1组的刺激效应(34/35,97.1%)显著高于第2组(13/20,65%)(P<0.025)。随后,在29例TSAb阴性患者中,检测到26例(89.7%)有sTSAb。最后,对格雷夫斯病抗甲状腺药物治疗停药后复发的格雷夫斯病患者和寂静性甲状腺炎患者的sTSAb、TSAb和促甲状腺素受体抗体(TBII)进行了比较。在所有14例复发患者中均检测到sTSAb,但9例寂静性甲状腺炎患者均未检测到可检测的sTSAb。相比之下,在14例复发病例中,仅7例(50.0%)检测到TSAb和TBII活性。本文表明,尽管其潜在机制尚不清楚,但较高PEG浓度的检测方法对于格雷夫斯病停药后的诊断和随访具有敏感性、特异性且有用。